Company Overview
ProQR Therapeutics N.V. operates as a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic medicines, specifically utilizing its proprietary Axiomer RNA editing technology to address genetic disorders with significant unmet medical needs. The firm functions within the broader Healthcare sector and the specialized Biotechnology industry, a space characterized by high research and development costs and long timelines to commercialization. As of the latest data, the company carries a market capitalization of $166.47M and generates annual revenue of $16.35M TTM, supported by a workforce of 186 employees. These financial figures indicate that ProQR maintains a relatively small market presence typical of clinical-stage entities that have not yet achieved full commercial product launch, reflecting a business model focused on capitalizing on future potential rather than current profitability.
Financial Health
The company reported revenue of $16.35M TTM alongside a net income of $-42,184,000 and an EBITDA of $-42,544,000, revealing a substantial gap between top-line generation and bottom-line performance that highlights a cost structure dominated by heavy investment in research, development, and operational expenses. This negative free cash flow of $-32,042,376 demonstrates that the company is consuming cash reserves to fund its clinical programs rather than generating liquidity from operations, which limits immediate financial flexibility without external financing. Profitability metrics are negative across the board, with a gross margin of 100.0%, an operating margin of -192.9%, and a profit margin of -258.1%; the perfect gross margin suggests no cost of goods sold at this stage, while the deep operating and profit losses indicate that current revenue is insufficient to cover overhead and R&D expenditures. On the balance sheet, ProQR holds $92.41M in cash against $15.96M in debt, resulting in a debt-to-equity ratio of 32.33, which suggests a conservative leverage position where cash significantly outweighs liabilities. The current ratio stands at 3.09, indicating that the company possesses more than three times the current assets needed to cover its short-term obligations, thereby signaling strong short-term liquidity despite ongoing losses. Furthermore, the return on equity is -61.2% and the return on assets is -19.3%, metrics that reveal management is currently deploying capital to generate value for shareholders through growth initiatives rather than immediate profit generation, as negative returns are standard for companies in the clinical development phase.
Valuation Assessment
Valuation metrics for ProQR present a complex picture due to the lack of earnings, with a trailing P/E ratio of N/A and a forward P/E of -3.36; the negative forward P/E implies that the market is pricing in expected earnings growth that has not yet materialized or is based on projected losses rather than current profitability. The price-to-book ratio is 2.90, indicating that the market values the company at nearly three times its book value, a premium that reflects the potential worth of its intellectual property and pipeline assets rather than its tangible assets alone. Alternative valuation measures such as a price-to-sales ratio of 10.18 and an EV/EBITDA of -2.12 suggest that investors are willing to pay a significant multiple of revenue for the company, anticipating future commercial success from its RNA editing platform. Regarding trading ranges, the stock has a 52-week high of $3.10 and a 52-week low of $1.07, and without the specific current price listed in the provided facts, the exact percentage deviation from these levels cannot be calculated, though the wide spread indicates high volatility within the trading period. The beta value is 0.09, which is exceptionally low for a biotechnology stock, suggesting that the share price exhibits minimal volatility relative to the broader market and moves independently of general market swings.
Growth & Income
Revenue growth year-over-year is recorded at 6.1%, while earnings growth is listed as N/A, indicating that the company has not yet achieved positive earnings to calculate a growth rate, and thus revenue expansion is the primary driver of scale at this stage. Since the company reports a net income of $-42,184,000, it does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available capital and cash flows back into its research and development pipeline rather than distributing income to shareholders. The absence of a dividend program aligns with the strategic priority of funding clinical trials and platform development to reach commercial milestones. Consequently, the overall growth and income profile is characterized by steady single-digit revenue expansion funded entirely by internal cash reserves and external financing, with no current income distribution to investors.